- Home
- ALNY vs CAH Comparison
ALNY vs CAH Comparison
Compare ALNY & CAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CAH
- Stock Information
- Founded
- ALNY 2002
- CAH 1979
- Country
- ALNY United States
- CAH United States
- Employees
- ALNY N/A
- CAH N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CAH Other Pharmaceuticals
- Sector
- ALNY Health Care
- CAH Health Care
- Exchange
- ALNY Nasdaq
- CAH Nasdaq
- Market Cap
- ALNY 38.1B
- CAH 32.3B
- IPO Year
- ALNY 2004
- CAH N/A
- Fundamental
- Price
- ALNY $303.77
- CAH $155.47
- Analyst Decision
- ALNY Strong Buy
- CAH Buy
- Analyst Count
- ALNY 25
- CAH 15
- Target Price
- ALNY $324.54
- CAH $146.67
- AVG Volume (30 Days)
- ALNY 1.1M
- CAH 2.1M
- Earning Date
- ALNY 07-31-2025
- CAH 05-01-2025
- Dividend Yield
- ALNY N/A
- CAH 1.31%
- EPS Growth
- ALNY N/A
- CAH 155.27
- EPS
- ALNY N/A
- CAH 6.38
- Revenue
- ALNY $2,348,099,000.00
- CAH $222,286,000,000.00
- Revenue This Year
- ALNY $30.28
- CAH N/A
- Revenue Next Year
- ALNY $30.25
- CAH $9.23
- P/E Ratio
- ALNY N/A
- CAH $24.38
- Revenue Growth
- ALNY 17.21
- CAH 0.86
- 52 Week Low
- ALNY $147.25
- CAH $93.17
- 52 Week High
- ALNY $307.85
- CAH $157.82
- Technical
- Relative Strength Index (RSI)
- ALNY 66.72
- CAH 67.42
- Support Level
- ALNY $284.73
- CAH $152.47
- Resistance Level
- ALNY $295.44
- CAH $154.73
- Average True Range (ATR)
- ALNY 9.24
- CAH 2.41
- MACD
- ALNY 1.41
- CAH -0.36
- Stochastic Oscillator
- ALNY 91.14
- CAH 76.95
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CAH Cardinal Health Inc.
Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.